RESUMO
OBJECTIVE: To determine the effects of neoadjuvant chemotherapy combined with breast-conserving surgery (BCS) on the breast cancer (BC) condition and immune and inflammatory indexes of patients with BC. METHODS: A total of 114 patients with BC admitted to the First People's Hospital of Shangqiu from March 2018 to March 2020 were retrospectively enrolled in this study. Fifty-four patients who underwent radical mastectomy alone were enrolled into the control group (Con group), and the other 60 patients who received neoadjuvant chemotherapy combined with BCS were assigned to the observation group (Obs group). The two groups were compared in terms of surgical indexes, therapeutic effects, immune indexes including immunoglobulin IgG, IgA, IgM, and inflammatory indexes. Cox regression analysis was conducted to analyze the independent prognostic factors of overall survival (OS) and disease-free survival (DFS). RESULTS: After therapy, the Obs group yielded a significantly higher effective therapy rate than the Con group and experienced notably shorter hospital stay and operation time than the Con group. In addition, the Obs group showed significantly higher levels of IgG, IgA and IgM and significantly lower levels of TNF-α and IL-6 than the Con group after therapy. According to Cox regression analysis, clinical stage and HER2 were independent prognostic factors impacting patients' OS and DFS. CONCLUSION: Neoadjuvant chemotherapy combined with BCS can substantially alleviate the disease condition, effectively improve the immune ability, and lower the inflammation level of BC patients, without impacting their 2-year OS and DFS.